Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selectis HealthGBCS +0.92%43 3-Year EBITDA Growth Rate is 10.20% as of Jun. 2026. GuruFocus rates GBCS with a GF Score™ of 43/100 and a GF Value™ of $1.78 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Selectis Health ranks better than 50.38% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Selectis Health was 166.40% per year. The lowest was -41.10% per year. And the median was -13.05% per year.
Selectis Health (OTCPK:GBCS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Selectis Health 3-Year EBITDA Growth Rate Related Terms
GBCS vs ADIA, CCM, SYRA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Selectis Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selectis Health 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Selectis Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Selectis Health's 3-Year EBITDA Growth Rate falls into.
Selectis Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.20% mean?
Selectis Health (GBCS) has a 3-Year EBITDA Growth Rate of 10.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Selectis Health and its competitors. According to the industry distribution chart, Selectis Health ranks #261 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 49.6%.
Is Selectis Health's 3-Year EBITDA Growth Rate too high?
Selectis Health's current 3-Year EBITDA Growth Rate is 10.20%. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Selectis Health's value of 10.20% is 3% above this industry median. Based on the distribution chart, Selectis Health ranks #261 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Selectis Health has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selectis Health's 3-Year EBITDA Growth Rate compare to ADIA and CCM?
According to the Healthcare Providers & Services industry distribution chart, Selectis Health ranks #261 out of 526 companies for 3-Year EBITDA Growth Rate. This puts Selectis Health in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Selectis Health's value of 10.20% is 3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selectis Health's current 3-Year EBITDA Growth Rate of 10.20% is 3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Selectis Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selectis Health's current 3-Year EBITDA Growth Rate is 10.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selectis Health stock overvalued right now?
Based on GuruFocus' analysis, Selectis Health (GBCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.78, compared to a current price of $5.47 — trading 207.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.20% and 3% above the Healthcare Providers & Services industry median of 9.90. Selectis Health's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Selectis Health (GBCS), the current 3-Year EBITDA Growth Rate is 10.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selectis Health (GBCS) Overvalued in 2026?
Based on GuruFocus' analysis, Selectis Health stock appears to be overvalued.
The current stock price of $5.47 is trading 207.3% above its estimated GF Value™ of $1.78.
GuruFocus considers Selectis Health to be Significantly Overvalued.
Key valuation signals for GBCS:
3-Year EBITDA Growth Rate: 10.20%
GF Value™: $1.78 vs. price of $5.47 (207.3% above fair value)
Industry Position: 3% above the Healthcare Providers & Services median (#261 of 526)
No single metric tells the full story. See the GBCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selectis Health Inc owns and operates medical care facilities in the healthcare industry. The company acquires, develops, leases, and manages healthcare real estate and provides healthcare operations through its wholly-owned subsidiaries. The portfolio is comprised of investments in the following healthcare operations: (i) senior housing (including independent and assisted living) and (ii) post-acute/skilled nursing. It makes investments within the healthcare operations using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008, which represents investments in senior housing operations, and (vi) owning healthcare operations.
43GF Score
Get the complete analysis for GBCS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GBCS has been successfully added to your 
